Presidio Medical

Presidio Medical operates in medical devices and neurotechnology, developing an implanted neuromodulation system intended to address chronic nociceptive pain. Its stated technical distinction is Ultra Low Frequency (ULF™) electrical stimulation delivered through implanted leads, with the product description framing the approach around reducing neuronal responses. Patent activity also points to work on nerve-conduction block, including direct-current methods. The company is private and has raised $102 million across three disclosed rounds, including a $72 million Series C led by Deerfield in 2023. That financing places it among venture-backed developers advancing device-based therapies, but funding alone does not establish commercial scale or clinical advantage. The most meaningful competitive questions are therefore whether ULF stimulation can demonstrate differentiated safety and efficacy, how it compares with established neuromodulation approaches in clinical evidence, and whether the system can progress through regulatory and commercialization requirements. IDE approval for a clinical study was announced in June 2025; study results and market adoption are not established here.

Presidio Medical’s disclosed growth path has been shaped by staged financing and clinical development. A $30 million Series B led by Invus Opportunities followed on Jul 14, 2020. On Jun 26, 2023, Presidio Medical announced a $72 million Series C led by Deerfield, bringing disclosed total funding to $102 million. The next clear inflection point is the Jun 12, 2025 announcement of IDE approval for a clinical study of its ULF™ neuromodulation technology, alongside the appointment of CFO Dimas Jiménez. That combination signals a shift toward clinical execution and preparation for potential commercialization, rather than evidence that commercialization has already occurred. Patent applications concerning nerve-conduction block through Feb 14, 2025 indicate continued development of the underlying technical approach.